University of Washington, Seattle, WA 98109, USA.
J Clin Oncol. 2011 Apr 20;29(12):1539-46. doi: 10.1200/JCO.2010.30.6308. Epub 2011 Mar 21.
Merkel cell carcinoma (MCC) is a polyomavirus-associated skin cancer that is frequently lethal and lacks established prognostic biomarkers. This study sought to identify biomarkers that improve prognostic accuracy and provide insight into MCC biology.
Gene expression profiles of 35 MCC tumors were clustered based on prognosis. The cluster of genes overexpressed in good-prognosis tumors was tested for biologic process enrichment. Relevant mRNA expression differences were confirmed by quantitative polymerase chain reaction and immunohistochemistry. An independent set of 146 nonoverlapping MCC tumors (median follow-up, 25 months among 116 living patients) was employed for biomarker validation. Univariate and multivariate Cox regression analyses were performed.
Immune response gene signatures were prominent in patients with good prognoses. In particular, genes associated with cytotoxic CD8+ lymphocytes were overexpressed in tumors from patients with favorable prognoses. In the independent validation set, cases with robust intratumoral CD8+ lymphocyte infiltration had improved outcomes (100% MCC-specific survival, n = 26) compared with instances characterized by sparse infiltration (60% survival, n = 120). Only stage and intratumoral CD8 infiltration (but not age, sex, or CD8+ lymphocytes localized to the tumor-stroma interface) were significant in both univariate and multivariate Cox regression analyses. Notably, traditional histologic identification of tumor-infiltrating lymphocytes was not a significant independent predictor of survival.
Intratumoral CD8+ lymphocyte infiltration can be readily assessed on paraffin-embedded tissue, is independently associated with improved MCC-specific survival, and therefore, may provide prognostic information that enhances established MCC staging protocols.
默克尔细胞癌(MCC)是一种与多瘤病毒相关的皮肤癌,通常具有致命性,且缺乏既定的预后生物标志物。本研究旨在寻找可提高预后准确性并深入了解 MCC 生物学的生物标志物。
根据预后对 35 例 MCC 肿瘤的基因表达谱进行聚类。检测高预后肿瘤中过表达的基因簇的生物学过程富集情况。通过定量聚合酶链反应和免疫组织化学验证相关 mRNA 表达差异。采用 146 例非重叠 MCC 肿瘤的独立样本(中位随访时间为 116 例存活患者中的 25 个月)进行生物标志物验证。进行单变量和多变量 Cox 回归分析。
免疫反应基因特征在预后良好的患者中突出。特别是与细胞毒性 CD8+淋巴细胞相关的基因在预后良好的肿瘤中过表达。在独立验证组中,具有丰富的肿瘤内 CD8+淋巴细胞浸润的病例具有更好的结局(100%的 MCC 特异性生存率,n=26),而浸润稀疏的病例(60%的生存率,n=120)则较差。只有分期和肿瘤内 CD8 浸润(而非年龄、性别或位于肿瘤-基质界面的 CD8+淋巴细胞)在单变量和多变量 Cox 回归分析中均有意义。值得注意的是,传统的组织学识别肿瘤浸润淋巴细胞并不是生存的独立预测因素。
肿瘤内 CD8+淋巴细胞浸润可在石蜡包埋组织上进行评估,与 MCC 特异性生存的改善独立相关,因此可能提供增强既定 MCC 分期方案的预后信息。